COMP <GO>
HIMS vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Hims & Hers Health Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: HIMS 5
— ABBV 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: HIMS
LAST: $27.68 (-6.71%) • MKT CAP: $6.92B
options-implied-move
7.10%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HIMS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HIMS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.80% | 70.20% | +3.60 | HIMS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.40% | 29.00% | -20.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 37.7x | 33.3x | +4.40 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 2.81% | 3.47% | -0.66 | ABBV | /fcf-yield <GO> |
| Operating Margin | 4.50% | 24.60% | -20.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 5.50% | 6.90% | -1.40 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 59.00% | 8.60% | +50.40 | HIMS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.95 | 5.33 | -1.38 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | HIMS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.10% | 7.40% | -0.30 | HIMS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.9 | 72.8 | -27.87 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.15 | -0.10 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.3x | 113.1x | -67.80 | HIMS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.92B | $513.86B | -$506.94B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HIMS REV | ABBV REV | HIMS GROSS % | ABBV GROSS % | HIMS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.35B | $61.16B | 73.8% | 70.2% | $194.4M | $17.82B |
| FY 2024 | $1.48B | $56.33B | 79.5% | 70.0% | $184.6M | $17.83B |
| FY 2023 | $872.0M | $54.32B | 44.0% | 44.0% | $34.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HIMS // BETA 1.05
ABBV // BETA 1.15